Here, we hypothesized that underlying RAS activation may potentiate the levels of sNRP1 and its ligands (VEGF and SEMA3A) in hypoglycaemia-induced stress in type 2 diabetes (T2D), reflecting an increased risk for SARS-CoV-2 infection. This evidence concerns the gene SEMA3A and type 2 diabetes mellitus.